Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

May 31, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2027

Conditions

Early Breast Cancer

Interventions

DRUG

EG1206A

EG1206A 420mg is ongoing to be administered after 840mg loading dose.

DRUG

Perjeta

Perjeta 420mg is ongoing to be administered after 840mg loading dose.

Trial Locations (1)

Methodist Health System Clinical Research Institute, Dallas